Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares Outstanding (Weighted Average)
Others
Ratios

KalVista Pharmaceuticals (KALV) Net Income towards Common Stockholders: 2013-2025

Historic Net Income towards Common Stockholders for KalVista Pharmaceuticals (KALV) over the last 13 years, with Apr 2025 value amounting to -$183.5 million.

  • KalVista Pharmaceuticals' Net Income towards Common Stockholders rose 5.34% to -$42.3 million in Q2 2025 from the same period last year, while for Apr 2025 it was -$156.4 million, marking a year-over-year decrease of 65.27%. This contributed to the annual value of -$183.5 million for FY2025, which is 44.86% down from last year.
  • As of FY2025, KalVista Pharmaceuticals' Net Income towards Common Stockholders stood at -$183.5 million, which was down 44.86% from -$126.6 million recorded in FY2024.
  • Over the past 5 years, KalVista Pharmaceuticals' Net Income towards Common Stockholders peaked at -$82.3 million during FY2021, and registered a low of -$183.5 million during FY2025.
  • For the 3-year period, KalVista Pharmaceuticals' Net Income towards Common Stockholders averaged around -$134.3 million, with its median value being -$126.6 million (2024).
  • Data for KalVista Pharmaceuticals' Net Income towards Common Stockholders shows a maximum YoY plummeted of 182.80% (in 2021) over the last 5 years.
  • KalVista Pharmaceuticals' Net Income towards Common Stockholders (Yearly) stood at -$82.3 million in 2021, then remained steady at -$82.3 million in 2022, then declined by 12.83% to -$92.9 million in 2023, then plummeted by 36.31% to -$126.6 million in 2024, then crashed by 44.86% to -$183.5 million in 2025.